Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer – guidance (TA653)

Osimertinib is recommended as an option for epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults, only if their disease has progressed after first-line EGFR tyrosine kinase inhibitor.

Source:

National Institute for Health and Care Excellence